Greenwich LifeSciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLSI research report →
Range $50 – $50
Price Chart
About the company
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies.
- CEO
- Snehal S. Patel
- IPO
- 2020
- Employees
- 13
- HQ
- Stafford, TX, US
Get TickerSpark's AI analysis on GLSI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $224.72M
- P/E
- -9.94
- Fwd P/E
- 3.85
- PEG
- 0.76
- P/S
- 0.00
- P/B
- 71.82
- EV/EBITDA
- -9.96
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -793.76%
- ROIC
- -701.55%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,779+50.7%
- Op Income
- $-19,447,918
- Net Income
- $-19,358,218-11.2%
- EPS
- $-1.43-18.2%
- OCF Growth
- -36.4%
- FCF Growth
- -36.4%
- 52W High
- $34.10
- 52W Low
- $7.78
- 50D MA
- $18.28
- 200D MA
- $20.63
- Beta
- 1.45
- RSI (14)
- 44
- Avg Volume
- 154.63K
No earnings-call transcripts are available for GLSI yet.
- Free Float
- 50.3%
- Shares Outstanding
- 14.68M
- Float Shares
- 7.38M
of shares held by institutions
49 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 296.62K | ▲ 14.44K |
| California State Teachers Retirement System | 339 | ▼ 46 |
| Cwm, LLC | 52 | ▲ 52 |
| Sunbelt Securities, Inc. | 2 | 0 |
Held by 77 ETFs
Biggest fund positions in GLSI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 29, 26 | Patel Snehal | buy | 700 |
| Jul 28, 26 | Patel Snehal | buy | 1,500 |
| Jul 27, 26 | Patel Snehal | buy | 1,500 |
| Jul 24, 26 | Patel Snehal | buy | 1,100 |
| Jul 23, 26 | Patel Snehal | buy | 2,500 |
| Jan 13, 26 | Patel Snehal | buy | 1,800 |
| Jan 12, 26 | Patel Snehal | buy | 2,900 |
| Dec 31, 25 | Patel Snehal | buy | 4,300 |
| Dec 30, 25 | Patel Snehal | buy | 2,900 |
| Dec 18, 25 | Patel Snehal | buy | 4,100 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GLSI coverage
Recent articles, reports, and earnings notes.
No research on GLSI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GLSI report →Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
globenewswire.com · Aug 10
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
globenewswire.com · Jul 22
Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
globenewswire.com · Jul 20
Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01
globenewswire.com · Jul 16
Greenwich LifeSciences The Overlooked Need
seekingalpha.com · Jul 16
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
globenewswire.com · Jul 9
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026
globenewswire.com · Jun 1
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
globenewswire.com · Jun 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.